@article{JGO20099,
author = {Jessica M. Frakes and Yazan A. Abuodeh and Arash O. Naghavi and Michelle I. Echevarria and Ravi Shridhar and Mark Friedman and Richard Kim and Ghassan El-Haddad and Bela Kis and Benjamin Biebel and Jennifer Sweeney and Junsung Choi and Daniel Anaya and Anna R. Giuliano and Sarah E. Hoffe},
title = {Viral hepatitis associated hepatocellular carcinoma outcomes with yttrium-90 radioembolization},
journal = {Journal of Gastrointestinal Oncology},
volume = {9},
number = {3},
year = {2018},
keywords = {},
abstract = {Background: Viral associated (VA) malignancies have recently been correlated with improved outcomes. We sought to evaluate outcomes of patients with hepatocellular carcinoma (HCC) with and without viral hepatitis (hepatitis B and C) treated with lobar yttrium-90 radioembolization (Y-90 RE).
Methods: After IRB approval, an institutional database of patients with HCC who received RE between 2009–2014 was queried and 99 patients were identified that received a total of 122 lobar RE. Charts were reviewed to capture previous treatments, viral hepatitis status, α-fetoprotein values (AFP), Child-Pugh class (CP), albumin-bilirubin score (ALBI), portal vein thrombosis (PVT), volumes treated and doses delivered. Comparison was made with Chi-square and Mann-Whitney U test. Intrahepatic control (IHC), extrahepatic control (EHC), progression free survival (PFS), and overall survival (OS) were calculated according to the Kaplan-Meier method stratified by cause of underlying liver disease (viral vs. non-viral) and survival differences were assessed via the log-rank test. Hazard ratios were calculated using Cox regression.
Results: Median follow up for VA HCC and non-VA (NVA) HCC patients was 10.9 months (range, 0.8–46.7 months) and 11.8 months (range, 1.1–62.8 months), respectively. Patients with VA HCC (n=44) were younger (P},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/20099}
}